|Day Low/High||7.78 / 9.14|
|52 Wk Low/High||2.08 / 10.89|
Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.
Norwegian Cruise Line was pulling down industry-peer Royal Caribbean Tuesday on lowered guidance.
ENDP shares surge on rare good news but asset sales may still be necessary.
Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.
Problems with mesh products and high leverage might scare away a potential buyer.
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.
The specialty pharmaceutical company gave investors a lot of news to digest -- and they fled.
the Sale of ASTORA Women's Health could bode well for the speciality pharma, as legal woes persist.
Mylan and Endo International look like bargains at current prices.
These biotech/pharma picks could give you a very happy new year.
Altera (ALTR) was the best performer on the S&P 500 Monday following reports the company has reopened negotiations with Intel (INTC).
Endo Pharmaceutical (ENDP) shares were on the move after the company agreed to buy privately-held Par Pharmaceutical Holdings for just over $8 billion in cash and stock.
Whether it's acquiring or the acquired, Mylan is building shareholder value.
This rollup name is on the stock-market equivalent of steroids.
Avon Gets Dinged, Endo's Irish Eyes, Piper Pipes Down, Bye-Bye BlackBerry and Walmart Gone Wild highlight Gregg Greenberg's list this week.